Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2008-01-22
2008-01-22
Kemmerer, Elizabeth C. (Department: 1649)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C530S387300, C530S387900, C536S023530, C435S328000, C435S331000, C424S139100, C424S141100
Reexamination Certificate
active
10497475
ABSTRACT:
Humanized forms of mouse antibody 10D5 that retain the binding properties of mouse 10D5 are disclosed. Also disclosed are processes for making the humanized antibody, intermediates for making the humanized antibodies, including, nucleotide sequences, vectors, transformed host cells, and methods of using the humanized antibody to treat, prevent, alleviate, reverse, or otherwise ameliorate symptoms or pathology or both, that are associated with Down's syndrome or pre-clinical or clinical Alzheimer's disease or cerebral amyloid angiopathy.
REFERENCES:
patent: 5441870 (1995-08-01), Seubert et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5538845 (1996-07-01), Knops et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5589154 (1996-12-01), Anderson
patent: 5593846 (1997-01-01), Schenk et al.
patent: 5604102 (1997-02-01), McConlogue et al.
patent: 5605811 (1997-02-01), Seubert et al.
patent: 5688651 (1997-11-01), Solomon
patent: 5693761 (1997-12-01), Queen et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 6175057 (2001-01-01), Mucke et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 2003/0165496 (2003-09-01), Basi et al.
patent: 613 007 (1994-08-01), None
patent: WO 96/18900 (1996-06-01), None
patent: WO 96/25435 (1996-08-01), None
patent: WO 98/44955 (1998-10-01), None
patent: WO 99/06066 (1999-02-01), None
patent: WO 99/27944 (1999-06-01), None
patent: WO 99/60024 (1999-11-01), None
patent: WO 00/72876 (2000-12-01), None
patent: WO 00/72880 (2000-12-01), None
patent: WO 00/77178 (2000-12-01), None
patent: WO 01/18169 (2001-03-01), None
patent: WO 02/46237 (2002-06-01), None
De Felice FG and Ferreira ST. beta-Amyloid production, aggregation, and clearance as targets for therapy in Alzheimer's disease. Cell Mol Neurobiol. 2002; 22(5-6): 545-563.
De Lustig ES et al. Peripheral markers and diagnostic criteria in Alzheimer's disease: Critical evaluations. Rev in Neurosciences, 1994; 5: 213-224.
Hartman RE et al. Treatment with an amyloid-beta antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer's disease. J Neurosci, 2005; 25(26): 6213-6220.
Johnson-Wood K et al. Amyloid precursor protein processing and Abeta42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci USA, 1997, 94: 1550-1555.
Kimchi EY et al. Analysis of cerebral amyloid angiopathy in a transgenic mouse model of Alzheimer disease using in vivo multiphoton microscopy. J. Neuropathol Exp Neurol, 2001; 60(3): 274-279.
Münch G and Robinson SR. Potential neurotoxic inflammatory response to Abeta vaccination in humans. J Neural Transm, 2002; 109: 1081-1087.
Small GW et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA, 2000; 97:6037-6042.
Vickers JC. A vaccine against Alzheimer's disease, developments to date. Drugs Aging, 2002, 19(7): 487-494.
Jones, PT, et al., “Replacing the complementarity-determining regions in a human antibody with those from a mouse,” Nature, vol. 321, pp. 522-525, May 29, 1986.
Frenkel, D, et al, “N-terminal EFRH sequence of Alzheimer's β-amylod peptide represents the epitope of its anti-aggregating antibodies,” J. Neuroimmunol., vol. 88, No. 1-2, pp. 85-90, Aug. 1, 1998.
Frenkel, D, et al., “High affinity binding of monoclonal antibodies to the sequential epitope EFRH of β-amyloid peptide is essential for modulation of fibrillar aggregation,” J. Neuroimmunol., vol. 95, No. 1-2, pp. 136-142, Mar. 1, 1999.
Parvizi J, et al., “The Selective Vulnerability of Brainstem Nuclei to Alzheimer's Disease,”Ann Neurol., vol. 49, No. 1, pp. 53-66, Jan. 2001.
Seubert, P, et al., “Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids,” Nature, vol. 359, pp. 325-327, 1992.
Van Gool, WA, et al., “Concentrations of amyloid-β protein in cerebrospinal fluid increases with age in patients free from neurodegenerative disease,” Neuroscience Lett., vol. 172, pp. 122-124, 1994.
Tabaton, M, el al., “Soluble Amyloid β-Protein is a Marker of Alzheimer Amyloid in Brain but Not in Cerebrospinal Fluid,” Biochemical and Biophysical Research Communications, vol. 200, No. 3, pp. 1598-1603, May 16, 1994.
Walker, L, et al., “Labeling of Cerebral Amyloid In Vivo with a Monoclonal Antibody,” J Neuropathol Exp Neurol., vol. 53, No. 4, pp. 377-383, Jul. 1994.
Nitsch, RM, et al., “Cerebrospinal Fluid Levels of Amyloid β-Protein in Alzheimer's Disease: Inverse Correlation with Severity of Dementia and Efect of Apolipoprotein E Genotype,” Annals Neurology, vol. 37, pp. 512-518, 1995.
Gomez-Isla, T, et al., A Novel Presenilin-1 Mutation: Increased β-Amyloid and Neurofibrillary Changes, Annals Neurology, vol. 41, pp. 809-813, 1997.
Schenk, D, et al., “Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse,”Nature, vol. 400, pp. 173-177, 1999.
Bard, F, et al., “Antibodies against Abeta reduce Amyloid Burden In Vivo,” Society for Neuroscience Abstracts, vol. p. 1059, Nov. 4, 2000.
Bard, F, et al., “Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease,”Nature Med., vol. 6, No. 8, pp. 916-919, 2000.
Chothia, C, et al., “Canonical Structures for the Hypervariable Regions of Immunoglobulins,”,J. Mol. Biol, vol. 196, pp. 901-917, 1987.
Chothia, C, et al., et al., “Conformations of imunoglobulin hypervariable regions,”,Nature, vol. 342, pp. 878-883, Dec. 21-28, 1989.
Queen, et al., “A humanized antibody that binds to the interleukin 2 receptor,”Proc. Natl. Acad. Sci. USA, vol. 86, pp. 10029-10033, Dec. 1989.
Co, MS, et al., “Humanized antibodies for antiviral therapy,”Proc. Natl. Acad. Sci. USA, vol. 88, pp. 2869, Apr. 1991.
Remington's Pharmaceutical Sciences, 18thEdition, Mack Publishing Co., Easton PA, pp. 1481-1498, 1504-1512, and 1519-1580, 1990.
Hyman, B., et al., “Kunitz Protease Inhibitor-Containing Amyloid β Protein Precursor Immunoreactivity in Alzheimer's disease,”J. Neuropath. Exp. Neurol., vol. 51, No. 1, pp. 76-83, Jan. 1992.
Walker, L, et al., “Labeling of β-Amyloid In Vivo,” (Abstract) Neurobiol. Aging, vol. 13, Supl. 1, S23, 1992.
Hanan, E, et al., “Inhibitory Effect of Monoclonal Antibodies on Alzheimer's β-Amyloid Peptide Aggregation”Int. J. Exp. Clin. Invest., vol. 3, pp. 130-133, 1996.
Solomon, B, et al., “Monoclonal antibodies inhibit n vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide,”Proc Natl Acad Sci U S A., vol. 93, No. 1, pp. 452-455, Jan. 1996.
Friedland, RP, et al., “Neuroimaging of Vessel Amyloid in Alzheimer's Disease,” Ann. NY Acad. Science, 826, pp. 242-247, 1997.
Goldman, DL, et al., “Pharmacokinetics and Biodistribution of a Monoclonal Antibody to Cryptococcus Neoformans Capsular Polysaccharide Antigen . . . ,”Journal of Medical&Veterinary Mycology, vol. 35, pp. 271-278, 1997.
Solomon, B, et al., “Disaggregation of Alzheimer β-amyloid by site-directed mAb,”Proc. Natl. Acad. Sci.,, vol. 94, pp. 4109-4112, 1997.
St. George-Hyslop, P, et al., “Antibody clears senile plaques,”Nature, vol. 400, pp. 116-117, Jul. 8, 1999.
Blass, JP, “Immunologic Treatment of Alzheimer's Disease,”New Engl. J. Med. vol. 341, No. 22, pp. 1694-1695, Nov. 25, 1999.
Schenk, D, et al., “A possible vaccine for treatment of AD,” World Alzheimer's Congress 2000, Plenary Session III, 605, Washington, D.C., Jul. 11, 2000.
Bacskai BJ, et al., “Imaging of amyloid-â deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy,” Nature Medicine vol. 7, No. 3, pp. 369-372, Mar. 2001.
Hinton Paul Robert
Vasquez Maximiliano J.
Ballard Kimberly A.
Eli Lilly and Company
Kelley James J.
Kemmerer Elizabeth C.
Stewart Mark J.
LandOfFree
Humanized antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Humanized antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Humanized antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3927765